Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s refuse-to-file letter for Firdapse in two ultra-rare neuromuscular disorders does not make judgments about the drug’s safety or efficacy, says Catalyst.


Related Content

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing
Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune
Breakthrough Pace Shows No Signs Of Slowing
BioMarin Launches Firdapse In Germany And The UK
FDA To Facilitate 4-AP Compassionate Use INDs For MS, Axelrad Says


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts